Adalimumab
Trovati 19 articoli
- TNF-alpha antagonists associated with serious skin reactions
- Safety reviews of tumor necrosis factor-alpha ( TNF-a ) antagonists, Infliximab ( Remicade ), Etanercept ( Enbrel ), and Adalimumab ( Humira ) identified rare cases of serious skin reactions, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, associated with ... (Leggi Articolo)
- Autoimmune disease: cardiovascular benefits of anti-TNF therapy in rheumatoid arthritis
- A chronic autoimmune disease, rheumatoid arthritis is characterized by persistent inflammation of the synovial membrane and progressive joint destruction. Beyond loss of mobility, sufferers face a high risk of heart failure. An inflammatory cytokine known for contributing to the development of ... (Leggi Articolo)
- TNF-alpha inhibition linked to invasive fungal infections
- Tumor necrosis factor a ( TNF- alpha ) blockade has emerged as a useful therapy for collagen vascular diseases or graft-vs-host disease. Fungal infections complicating such therapy have been reported sporadically. Of the 281 cases of invasive fungal infections associated with TNF-alpha inhibit... (Leggi Articolo)
- Several serious reactions linked to TNF-alpha inhibitors
- Tumour necrosis factor alpha ( TNF-alpha ) is a cellular protein produced by the immune system and is an important mediator of many diseases, including inflammatory arthritis and inflammatory bowel disease. Currently, three tumour necrosis factor alpha blocking agents are registered in Australi... (Leggi Articolo)
- NICE: Adalimumab and Rituximab for the treatment of arthritis
- The NICE ( National Institute for Health and Clinical Excellence ) has published final guidance on the use of Rituximab ( Mabthera; US: Rituxan ) for the treatment of rheumatoid arthritis and Adalimumab ( Humira ) for the treatment of psoriatic arthritis, as part of its rapid single technology ap... (Leggi Articolo)
- Crohn's disease: FDA has approved Humira
- The FDA ( Food and Drug Administration ) has approved Humira ( Adalimumab ) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans. Humira is a human-derived, genetically-engine... (Leggi Articolo)
- TNF-blocking agents: Humira is effective in plaque psoriasis
- Two clinical trials of Humira ( Adalimumab ), REVEAL and CHAMPION, have demonstrated promising results in psoriasis. Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form of psoriasis appears as red,... (Leggi Articolo)
- Humira for maintaining clinical remission in patients with Crohn's disease
- The results from a study showing patients with moderate to severely active Crohn's disease treated with Adalimumab ( Humira ) were more likely to maintain clinical remission through one year than patients receiving a placebo, regardless of the frequency of the dosing regimen. Data from C... (Leggi Articolo)
- Combination therapy, Adalimumab plus Methotrexate, for achieving remission of early rheumatoid arthritis
- Two-year study of patients with early, aggressive disease demonstrates significantly superior results of anti-TNF plus DMARD therapy over either therapy alone. A chronic and potentially crippling inflammatory disorder, rheumatoid arthritis progressively wears away the cartilage and bone. Joint... (Leggi Articolo)
- Inflammatory bowel diseases: biological therapies
- IBD ( inflammatory bowel diseases ) is a term referring to several chronic diseases that cause inflammation of the intestines, including ulcerative colitis and Crohn's disease. Symptoms for both conditions are very similar and it is often difficult for physicians to differentiate between the t... (Leggi Articolo)
- Humira plus Methotrexate effective for long standing rheumatoid arthritis
- Combined treatment with Adalimumab ( Humira ) and Methotrexate is about five times more effective than Methotrexate alone in people with long-standing rheumatoid arthritis. In six randomized controlled trials, comprising 2381 people with at least 10 years of the disease, the authors report tha... (Leggi Articolo)
- Rheumatoid arthritis, early therapy with Adalimumab and Methotrexate may affect long-term disease progression
- Patients with rheumatoid arthritis, whose joint damage is inhibited through a combination therapy of Adalimumab ( Humira ) and Methotrexate early in the course of their disease are less likely to experience further damage two years later. The PREMIER study found that patients with early rheuma... (Leggi Articolo)
- Europe: Humira for the treatment of psoriatic arthritis and early rheumatoid arthritis
- European Commission approved Humira ( Adalimumab ) as a treatment for psoriatic arthritis and as first-line treatment of severe rheumatoid arthritis ( RA ) in Europe. The approval for psoriatic arthritis marks the second indication for Humira, while the early rheumatoid arthritis approval esta... (Leggi Articolo)
- CHMP recommends approval of Humira for psoriatic arthritis
- CHMP, the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency ( EMEA ), has issued a positive opinion recommending approval of Adalimumab ( Humira ) for the treatment of psoriatic arthritis. The positive opinion for Adalimumab as a treatm... (Leggi Articolo)
- Efficacy of the treatment with Humira in patients with Crohn’s disease
- A Phase III study showed that patients with moderate to severely active Crohn's disease treated with Adalimumab ( Humira ) have seen continuing improvements in clinical response and clinical remission. After 24 weeks, an improvement in disease response, as measured by a decrease of more than ... (Leggi Articolo)
- Rheumatoid arthritis, TNF-alpha blockers may cause skin diseases
- A prospective cohort study found that Tumour Necrosis Factor alpha ( TNF-alpha ) blocking agents, trigger skin conditions in 25% of patients with rheumatoid arthtitis. TNF-alpha blocking agents has had a remarkable effect on disease activity in a number of rheumatic diseases, including rheumat... (Leggi Articolo)
- Psoriatic arthritis, FDA approves Humira for reducing signs and symptoms of active arthritis
- FDA ( U.S. Food and Drug Administration ) approved Humira ( Adalimumab ) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis, a chronic disease that combines the symptoms of arthritis, including joint pain and inflammation, with those of psoriatic skin dise... (Leggi Articolo)
- FDA approves Humira for first-line treatment of moderate to severe rheumatoid arthritis
- The FDA ( U.S. Food and Drug Administration ) approved Humira ( Adalimumab ) for first-line treatment of recent onset moderate to severe rheumatoid arthritis ( RA ). The approval offers RA patients an important therapeutic option early in the course of their disease, when there is a critical win... (Leggi Articolo)
- TNF blockers linked to lymphoma risk
- The manufacturers of the drugs Humira ( Adalimumab ), Remicade ( Infliximab ) and Enbrel ( Etanercept ) have added new safety information to the labels for these products about malignancies. These three drugs are tumor necrosis factor ( TNF ) blocking agents, and they're used to treat rheumatoi... (Leggi Articolo)
